<h3 class='section'>Important Safety Information</h3><h3 class='section'>CONTRAINDICATIONS</h3><p>TREMFYA<sup>®</sup> is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.</p>
<br>
<p>WARNINGS AND PRECAUTIONS</p>
<p>Infections</p>
<p>TREMFYA<sup>®</sup> may increase the risk of infection. Treatment with TREMFYA<sup>®</sup> should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.</p>
<br>
<p>Consider the risks and benefits of treatment prior to prescribing TREMFYA<sup>®</sup> in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA<sup>®</sup> to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA<sup>®</sup> until the infection resolves.</p>
<br>
<p>Pre-Treatment Evaluation for Tuberculosis (TB)</p>
<p>Evaluate patients for TB infection prior to initiating treatment with TREMFYA<sup>®</sup>. Initiate treatment of latent TB prior to administering TREMFYA<sup>®</sup>. Monitor patients for signs and symptoms of active TB during and after TREMFYA<sup>®</sup> treatment. Do not administer TREMFYA<sup>®</sup> to patients with active TB infection.</p>
<br>
<p>Hypersensitivity Reactions</p>
<p>Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA<sup>®</sup>, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA<sup>®</sup> and initiate appropriate therapy.</p>
<br>
<p>Immunizations</p>
<p>Prior to initiating TREMFYA<sup>®</sup>, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA<sup>®</sup>.</p>
<br>
<h3 class='section'>ADVERSE REACTIONS</h3><p>Most common (≥1%) adverse reactions associated with TREMFYA<sup>®</sup> include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.</p>
<br>
<p>Please read the full Prescribing Information and Medication Guide for TREMFYA<sup>®</sup>. Provide the Medication Guide to your patients and encourage discussion.</p>
<br>
<p>cp-82625v1</p>
